-
Statement calls for greater efforts in smoking cessation. Tobacco use should be evaluated as a confounding factor in clinical trials. Surveys show tobacco use is often not measured. WASHINGTON, D.C. — An American Association for Cancer Research (AACR) statement calls on the oncology community to...
Posted to
News
by
AACR News
on
Tue, Apr 9 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, tobacco, smoking, Clinical Cancer Research, policy statement, clinical trials, Annual Meeting, AACR Annual Meeting 2013, 2013 Annual Meeting, confounding factor
-
Preclinical combination of an EGFR inhibitor and a COX-2 inhibitor was effective. Advanced oral precancerous lesions were eliminated in three patients. Drug combination could be a new strategy to prevent head and neck cancers. PHILADELPHIA — A new drug combination shows promise in reducing the...
Posted to
News
by
AACR News
on
Tue, Feb 19 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, journal, high-risk, squamous cell carcinoma, head and neck cancer, clinical research, precancer, combination, Dr. Dong Moon Shin, oral precancerous lesions
-
Model predicts immediate treatment confers only modest extension of life. Surveillance affords patients years of treatment-free life. Data support continued adoption of surveillance approach. PHILADELPHIA — A new research model has estimated that the difference in prostate cancer mortality among...
Posted to
News
by
AACR News
on
Mon, Sep 24 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, prostate cancer, journal, Watchful waiting, prostatectomy, Dr. Ruth Etzioni, active surveillance, low-risk prostate cancer
-
Denosumab decreased tumor presence in the entire cohort. Some patients experienced bone regrowth. Drug could be first medical alternative to radical surgery. PHILADELPHIA — Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor...
Posted to
News
by
AACR News
on
Fri, Sep 21 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, journal, denosumab, Dr. Sant P. Chawla, bone tumor, Phase II, giant-cell tumor of the bone
-
Denosumab reduced bone-related complications and need for radiation therapy. Treatment improved health-related quality of life. May replace standard bisphosphonate treatments like zoledronic acid. PHILADELPHIA — Treatment with denosumab resulted in a greater reduction in skeletal-related events...
Posted to
News
by
AACR News
on
Tue, Aug 14 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, women, journal, Zoledronic acid, metastatic breast cancer, Dr. Miguel Martin, denosumab, bone metastases
-
Final phase III trial analyses substantiate interim results that led to FDA approval. Crossover trial design worked and benefitted patients. Long-term overall survival benefit estimated with no new adverse events. PHILADELPHIA — Patients benefitted from an important design element in the pivotal...
Posted to
News
by
AACR News
on
Fri, Jun 1 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, sunitinib, journal, Clinical trial, Dr. George D. Demetri, gastrointestinal stromal tumor, GIST
-
Low oxygen (hypoxia) predicts prostate cancer recurrence after radiotherapy. Measuring prostate cancer hypoxia could help identify the best treatment for patients. New treatments that target prostate cancer hypoxia could improve patient outcome. CHICAGO — Hypoxia, or a lack of oxygen, in prostate...
Posted to
News
by
AACR News
on
Sat, Mar 31 2012
Filed under:
Filed under: Press Releases, Cancer, AACR, American Association for Cancer Research, Clinical Cancer Research, prostate cancer, meeting, 2012 Annual Meeting, Annual Meeting, hypoxia, AACR Annual Meeting 2012, Dr. Michael F. Milosevic
-
EWS is the second most common bone malignancy in children and adolescents. Combination therapy efficacious against chemotherapy-resistant EWS. The combination was safe, with manageable adverse events. CHICAGO — A combination of targeted therapies may be effective against relapsed or recurrent...
Posted to
News
by
AACR News
on
Sat, Mar 31 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, meeting, 2012 Annual Meeting, Annual Meeting, AACR Annual Meeting 2012, Dr. Aung Naing, Ewing’s sarcoma, mTOR inhibitor, IGF-1R inhibitor
-
Patients with pancreatic cancer often have a high prevalence of diabetes. Metformin was linked with a nearly twofold higher two-year survival rate. Patients prescribed metformin had a 32 percent reduced risk for death. PHILADELPHIA — Patients with diabetes and pancreatic cancer who are prescribed...
Posted to
News
by
AACR News
on
Sat, Mar 31 2012
Filed under:
Filed under: Press Releases, diabetes, Research, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, meeting, pancreatic cancer, 2012 Annual Meeting, Annual Meeting, AACR Annual Meeting 2012, Metformin, Dr. Donghui Li
-
SAN FRANCISCO — Progress in oncology drug development will take center stage Nov. 12-16, 2011, as thousands of scientists and industry experts convene at the Moscone Center West in San Francisco for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. “During the last...
Posted to
News
by
AACR News
on
Thu, Nov 10 2011
Filed under:
Filed under: Press Releases, San Francisco, Research, Treatment, Breast Cancer, Conference, Cancer, teleconference, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, meeting, National Cancer Institute, NCI, angiogenesis, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, EORTC, Dr. Kenneth C. Anderson, European Organisation for Research and Treatment of Cancer, Dr. James H. Doroshow, Moscone Center West
-
Vaccine is a recombinant poxviral compound. One patient with metastatic breast cancer had a sustained complete response. PHILADELPHIA — Treatment with a recombinant poxviral vaccine showed a positive response in both metastatic breast cancer and ovarian cancer, according to a trial published in...
Posted to
News
by
AACR News
on
Tue, Nov 8 2011
Filed under:
Filed under: Press Releases, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, women, ovarian cancer, journal, National Cancer Institute, NCI, Vaccine, Metastatic, therapeutic vaccine, Dr. James Gulley, complete response, cancer vaccine
-
Tweet • Uses HER2 as a target to selectively deliver toxins to cancer cells. • Designed to overcome issues of resistance with Herceptin. PHILADELPHIA — Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin...
Posted to
News
by
AACR News
on
Tue, Jul 26 2011
Filed under:
Filed under: Press Releases, Research, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, women, Jacek Capala, HER-2 positive, Trastuzumab, National Cancer Institute, HER2-Affitoxin, Herceptin, affibody, drug resistance, PE38, NCI
-
Tweet • Flu vaccine could be used to test immune response. • Patients presented with metastatic renal cell cancer. • Implications beyond quality of life and patient management. PHILADELPHIA — Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents...
Posted to
News
by
AACR News
on
Tue, Jun 28 2011
Filed under:
Filed under: Press Releases, Research, influenza, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, Radboud University Nijmegen Medical Center, sorafenib, Keith Flaherty, flu vaccine, immune system, metastatic renal cell cancer, Clinical Cancer Research, sunitinib, The Netherlands, Carla van Herpen